147 related articles for article (PubMed ID: 38500360)
41. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.
Madan A; Markison S; Betz SF; Krasner A; Luo R; Jochelson T; Lickliter J; Struthers RS
Pituitary; 2022 Apr; 25(2):328-339. PubMed ID: 35000098
[TBL] [Abstract][Full Text] [Related]
42. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
43. Treatment options for acromegaly.
Sheppard MC; Stewart PM
Metabolism; 1996 Aug; 45(8 Suppl 1):63-4. PubMed ID: 8769385
[TBL] [Abstract][Full Text] [Related]
44. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
45. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
46. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
Brabant G
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S15-20. PubMed ID: 12670296
[TBL] [Abstract][Full Text] [Related]
47. Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly.
Martín-Rodríguez JF; Muñoz-Bravo JL; Ibañez-Costa A; Fernandez-Maza L; Balcerzyk M; Leal-Campanario R; Luque RM; Castaño JP; Venegas-Moreno E; Soto-Moreno A; Leal-Cerro A; Cano DA
Sci Rep; 2015 Nov; 5():16298. PubMed ID: 26549306
[TBL] [Abstract][Full Text] [Related]
48. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
49. Monoclonal antibodies to growth hormone (GH) prolong liver GH binding and GH-induced IGF-I/IGFBP-3 synthesis.
Beauloye V; Muaku SM; Lause P; Portetelle D; Renaville R; Robert AR; Ketelslegers JM; Maiter D
Am J Physiol; 1999 Aug; 277(2):E308-15. PubMed ID: 10444427
[TBL] [Abstract][Full Text] [Related]
50. Autocrine secretion of insulin-like growth factor-I mediates growth hormone-stimulated DNA synthesis and proliferation in primary cultures of adult rat hepatocytes.
Kurihara K; Moteki H; Kimura M; Ogihara M
Eur J Pharmacol; 2021 Jan; 891():173753. PubMed ID: 33245901
[TBL] [Abstract][Full Text] [Related]
51. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
52. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
53. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
54. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.
Garrido MJ; Cendrós JM; Ramis J; Peraire C; Obach R; Trocóniz IF
J Clin Pharmacol; 2012 Apr; 52(4):487-98. PubMed ID: 21551318
[TBL] [Abstract][Full Text] [Related]
56. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
57. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
58. Pregnancy and acromegaly: a review.
Cheng V; Faiman C; Kennedy L; Khoury F; Hatipoglu B; Weil R; Hamrahian A
Pituitary; 2012 Mar; 15(1):59-63. PubMed ID: 21789529
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal antibodies to bovine growth hormone potentiate hormonal activity in vivo by enhancing growth hormone binding to hepatic somatogenic receptors.
Massart S; Maiter D; Portetelle D; Adam E; Renaville R; Ketelslegers JM
J Endocrinol; 1993 Dec; 139(3):383-93. PubMed ID: 8133207
[TBL] [Abstract][Full Text] [Related]
60. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
